诺华制药(NVS.US)对MorphoSys(MOR.US)发起收购要约收购价68欧元/股_老虎社区_美港股上老虎

诺华制药(NVS.US)对MorphoSys(MOR.US)发起收购要约收购价68欧元/股

智通财经网04-11

智通财经APP获悉，诺华制药(NVS.US)已经对德国癌症制药商MorphoSys(MOR.US)发起了收购要约，拟以每股68欧元或总计27亿欧元的现金收购该公司所有已发行股票。该报价较过去三个月内成交量加权平均价格溢价142%。该要约的接受期从今天开始，到2024年5月13日结束。据了解，今年2月，诺华制药与MorphoSys达成了一项自愿公开收购协议。该交易需符合惯例成交条件，包括至少65%的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2426253531?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20240411/20240411193309_72568.png?x-oss-process=image/format,jpg/quality,Q_80","is_english":false,"pubTime":"2024-04-11 19:32","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2426253531","market":"hk","top_or_hot":-1,"title":"诺华制药(NVS.US)对MorphoSys(MOR.US)发起收购要约 收购价68欧元/股","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，诺华制药(NVS.US)已经对德国癌症制药商MorphoSys(MOR.US)发起了收购要约，拟以每股68欧元或总计27亿欧元的现金收购该公司所有已发行股票。该报价较过去三个月内成交量加权平均价格溢价142%。该要约的接受期从今天开始，到2024年5月13日结束。据了解，今年2月，诺华制药与MorphoSys达成了一项自愿公开收购协议。该交易需符合惯例成交条件，包括至少65%的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1101291.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺华制药(NVS.US)对MorphoSys(MOR.US)发起收购要约 收购价68欧元/股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺华制药(NVS.US)对MorphoSys(MOR.US)发起收购要约 收购价68欧元/股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 19:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1101291.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，诺华制药(NVS.US)已经对德国癌症制药商MorphoSys(MOR.US)发起了收购要约，拟以每股68欧元或总计27亿欧元的现金收购该公司所有已发行股票。该报价较过去三个月内成交量加权平均价格溢价142%。该要约的接受期从今天开始，到2024年5月13日结束。据了解，今年2月，诺华制药与MorphoSys达成了一项自愿公开收购协议。该交易需符合惯例成交条件，包括至少65%的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1101291.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1101291.html","article_id":"2426253531","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20240411/20240411193309_72568.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426253531","pubTimestamp":1712835152,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"诺华制药已经对德国癌症制药商MorphoSys发起了收购要约，拟以每股68欧元或总计27亿欧元的现金收购该公司所有已发行股票。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01477":"欧康维视生物-B","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK1574":"生物医药B类股","NVS":"诺华","BK4007":"制药","BK4139":"生物科技","BK4588":"碎股","BK1191":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","MOR":"Morphosys AG","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4578":"CAR-T","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"Novartis Pharmaceuticals (NVS.US) launched an acquisition offer for MorphoSys (MOR.US) at a price of 68 euros per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1,"MOR":1,"01477":1},"content_text":"智通财经APP获悉，诺华制药(NVS.US)已经对德国癌症制药商MorphoSys(MOR.US)发起了收购要约，拟以每股68欧元或总计27亿欧元的现金收购该公司所有已发行股票。该报价较过去三个月内成交量加权平均价格溢价142%。该要约的接受期从今天开始，到2024年5月13日结束。据了解，今年2月，诺华制药与MorphoSys达成了一项自愿公开收购协议。该交易需符合惯例成交条件，包括至少65%的MorphoSys流通股接受收购要约，并获得监管部门的批准。据瑞银分析师估计，MorphoSys的关键实验药物pelabresib有70%的机会达到10亿欧元的最高收入。摩根士丹利分析师Mark  Purcell表示，两家制药商合作具有战略意义，因为MorphoSys一直在研究pelabresib与Jakafi联合使用的有效性。诺华制药在美国以外地区销售Jakafi。这笔交易预计将于2024年上半年完成。在交易完成之前，MorphoSys将继续作为一家独立的公司运营。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}